Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?
暂无分享,去创建一个
J. Shiraishi | A. Kubo | M. Takada | T. Kurata | T. Kawaguchi | K. Tsujino | T. Tsuji | T. Kawaguchi | A. Kubo | M. Takada